October 24, 2022

Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

NRG Oncology investigators analyzed clinical and digital histopathology data from five Phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multi-modal intelligence models (MMAI) that could outperform the National Comprehensive Cancer Network (NCCN) in the prediction of distant metastasis (DM) and other outcomes. MMAI models could, in fact, stratify patients into risk groups that more accurately reflected their prognosis in comparison to NCCN risk groups. These results were presented during the Plenary Session of the American Society for Radiation Oncology's Annual Meeting in October 2022.

Continue reading